Answers are grounded in this paper and cite their sources.
Retrospective analysis shows improved oncologic outcomes in selected patients with metastatic castration-sensitive prostate cancer, suggesting treatment efficacy.
Cytoreductive radical prostatectomy (cRP) appears to be a feasible and safe local treatment option in selected patients with mCSPC. In addition to cytoreductive benefit, cRP provides critical pathological information-particularly pTE-that correlates strongly with survival outcomes but cannot be predicted preoperatively. These findings support the incorporation of cRP as a diagnostic and therapeutic component within a multimodal treatment strategy for mCSPC.
No takes yet. Share an insight, caveat, or question.
Morozumi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: